An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

被引：0

作者：

Keunchil Park

Jin-Soo Kim

Joo-Hang Kim

Young-Chul Kim

Hoon-Gu Kim

Eun Kyung Cho

Jong-Youl Jin

Miyoung Kim

Angela Märten

Jin-Hyoung Kang

机构：

[1] Sungkyunkwan University School of Medicine,Division of Hematology

[2] Seoul Metropolitan Government Seoul National University Boramae Medical Center,Oncology, Department of Medicine Samsung Medical Center

[3] CHA University,Department of Internal Medicine

[4] Chonnam National University Medical School,CHA Bundang Medical Center

[5] CNU Hwasun Hospital,Department of Internal Medicine

[6] Gyeongsang National University College of Medicine and Gyeongsang National University Changwon Hospital,Gil Medical Center

[7] Gachon University College of Medicine,Bucheon St Mary’s Hospital

[8] The Catholic University of Korea,Department of Internal Medicine, Seoul St. Mary’s Hospital

[9] Boehringer Ingelheim Korea Ltd,undefined

[10] Boehringer Ingelheim International GmbH,undefined

[11] The Catholic University of Korea,undefined

来源：

BMC Cancer | / 21卷

关键词：

Afatinib; NSCLC; EGFR; Uncommon mutations; Brain metastases; Real world;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用